1:35:02
Buprenorphine and Opioid Use Disorder Management with Dr. Neal Christopher
Psychiatry & Psychotherapy
Overview
This video provides a comprehensive overview of buprenorphine for managing opioid use disorder, featuring Dr. Neal Christopher. It details the recent removal of the X waiver, explaining its implications for prescriber access. The discussion delves into the pharmacology of buprenorphine, highlighting its partial agonist activity at mu-opioid receptors, its safety profile with a ceiling effect, and the role of naloxone in combination formulations to deter misuse. Practical aspects of initiating and managing buprenorphine treatment are covered, including dosing strategies, dealing with precipitated withdrawal, and addressing patient deception. The video also touches upon the complexities of polysubstance use, the dangers of adulterated drug supplies (like fentanyl with xylazine), and the importance of patient-centered care, motivational interviewing, and long-term treatment maintenance.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- The DATA 2000 waiver previously required specific training for physicians to prescribe buprenorphine outside of specialized opioid treatment programs.
- This waiver aimed to increase access but was insufficient to combat the third wave of the opioid crisis, characterized by potent synthetic opioids like fentanyl.
- The Consolidated Appropriations Act of 2023 eliminated the X waiver, allowing any US-licensed prescriber with a DEA registration to prescribe buprenorphine.
- New prescribers or those renewing their DEA registration after June 27, 2023, must complete a one-time, 8-hour training on addiction treatment, unless board-certified in addiction medicine/psychiatry or have completed equivalent training in medical school.
The removal of the X waiver significantly broadens the availability of buprenorphine, enabling more healthcare providers, especially in primary care settings, to offer this crucial treatment for opioid use disorder.
Previously, a primary care physician might have been hesitant or unable to prescribe buprenorphine due to the X waiver requirements; now, they can prescribe it after completing the one-time training.
- Buprenorphine is a partial agonist at the mu-opioid receptor, meaning it binds strongly and occupies the receptor but only partially activates it, leading to a 'ceiling effect' that reduces overdose risk compared to full agonists.
- Its high binding affinity allows it to displace other opioids from the receptor, which can be beneficial but also precipitate severe withdrawal if taken too soon after other opioids.
- Buprenorphine also acts as an antagonist at the kappa-opioid receptor, contributing to its complex pharmacological profile.
- Formulations often include naloxone, an opioid overdose reversal agent, which is poorly bioavailable when taken sublingually as prescribed but will block buprenorphine if the medication is injected or misused, causing withdrawal.
Understanding buprenorphine's unique partial agonism and its interaction with other opioids is critical for safe initiation and to prevent precipitated withdrawal, a common barrier to treatment.
A patient taking fentanyl might experience severe, immediate withdrawal if they take buprenorphine too soon because the buprenorphine displaces the fentanyl from the mu-opioid receptors.
- Buprenorphine has a long half-life, allowing for less frequent dosing (often once daily) once a stable serum level is achieved, which can improve patient adherence and reduce cravings.
- It is primarily excreted via feces (about 80%) and secondarily via kidneys (about 20%).
- Metabolism occurs via CYP3A4, producing norbuprenorphine, which has weak activity.
- Medications that inhibit CYP3A4 (e.g., certain antifungals, macrolide antibiotics, HIV protease inhibitors) can increase buprenorphine levels, potentially requiring dose adjustments.
Knowledge of buprenorphine's long duration of action and potential drug interactions helps in managing patient expectations, optimizing dosing, and avoiding adverse effects.
A patient on an HIV protease inhibitor might metabolize buprenorphine more slowly, potentially requiring a lower dose to avoid excessive sedation or side effects.
- Initiation requires the patient to be in mild to moderate withdrawal (e.g., COWS score of 10-12 or higher) to avoid precipitated withdrawal.
- Traditional dosing involved small, incremental doses, but emergency departments often use a 'bridge protocol' with up to 16 mg of buprenorphine at once for patients in moderate to severe withdrawal.
- In outpatient settings, starting with 2-8 mg and titrating up based on patient response and follow-up is common, with many patients eventually reaching 16 mg or higher daily doses.
- Higher doses (up to 32 mg or more) may be necessary for individuals with high-dose or long-term fentanyl use, though evidence for efficacy beyond 32 mg for maintaining abstinence is limited.
Safe and effective initiation of buprenorphine is crucial for patient engagement and requires careful assessment of withdrawal severity and appropriate dosing.
An emergency department might administer 8 mg of buprenorphine twice daily to a patient in active withdrawal as part of a bridge program to stabilize them before outpatient follow-up.
- Patients with substance use disorder can develop sophisticated deception skills to maintain their use; building trust and open communication is essential, rather than a punitive approach.
- Polysubstance use, especially combining opioids with stimulants like methamphetamine, significantly increases overdose risk due to competing physiological effects and potential for masking symptoms.
- The increasing prevalence of adulterants like xylazine (a veterinary sedative) in street drugs complicates treatment, as naloxone is ineffective against xylazine, leading to dual respiratory depression.
- The illicit drug supply is unpredictable and often contaminated, making it difficult for patients to know what they are taking and increasing the risk of accidental overdose, even for experienced users.
Recognizing and addressing the complexities of deception, polysubstance use, and adulterated drugs is vital for accurate assessment and effective harm reduction strategies.
A patient might test positive for substances they deny using because the fentanyl they purchased was mixed with xylazine, a substance naloxone cannot reverse.
- Buprenorphine maintenance therapy is highly effective in preventing relapse and improving quality of life, with many patients achieving long-term sobriety.
- Discontinuing buprenorphine should be a gradual process, typically involving slow tapers over months or even years, to minimize withdrawal symptoms and relapse risk.
- Patients often face pressure from family or friends to stop medication, mistaking maintenance treatment for addiction; education is key to addressing this misconception.
- While long-term studies are ongoing, current evidence suggests a higher risk of relapse upon discontinuation, especially if done too quickly or without adequate support.
Long-term maintenance with buprenorphine is a valid treatment, and decisions about discontinuation should be patient-centered, evidence-based, and involve slow, supported tapers.
A patient on 16 mg of buprenorphine daily might be tapered by reducing their dose by 1-2 mg every 1-2 weeks, potentially taking many months to discontinue safely.
- Effective treatment integrates medication with psychosocial support, including motivational interviewing (MI) and acceptance and commitment therapy (ACT).
- MI helps address patient ambivalence towards treatment by exploring their values and motivations for change, reducing shame and fostering collaboration.
- Building a strong, trusting relationship with patients is paramount, allowing for honest conversations about challenges like relapse or deception without judgment.
- Providers should not give up on patients, as even small steps towards restoring relationships or addressing underlying issues can lead to significant progress and long-term recovery.
The therapeutic relationship and psychosocial interventions are as critical as medication in supporting patients through recovery, addressing underlying issues, and promoting sustained well-being.
Instead of confronting a patient about a positive drug screen with shame, a provider uses motivational interviewing to explore what might be missing in their life that led to relapse, focusing on restoring a damaged relationship with their mother.
Key takeaways
- The removal of the X waiver has democratized access to buprenorphine, making it a more accessible treatment option for opioid use disorder.
- Buprenorphine's partial agonism at mu-opioid receptors offers a safety ceiling, significantly reducing overdose risk compared to full opioid agonists.
- Careful timing of buprenorphine initiation is crucial to prevent precipitated withdrawal, a common and distressing side effect.
- High-potency synthetic opioids like fentanyl and adulterants like xylazine present significant challenges, increasing overdose risk and complicating treatment protocols.
- Dosing strategies for buprenorphine can be flexible, with higher doses sometimes necessary for individuals with severe opioid use disorder, particularly those using fentanyl.
- Building trust and employing motivational interviewing are essential components of effective buprenorphine treatment, addressing patient ambivalence and fostering long-term engagement.
- Long-term maintenance with buprenorphine is a recognized and effective treatment strategy, and discontinuation should be a slow, carefully managed process.
- The illicit drug supply's unpredictability and contamination pose major risks, underscoring the importance of harm reduction and patient education.
Key terms
BuprenorphineOpioid Use Disorder (OUD)X waiverPartial agonistMu-opioid receptorKappa-opioid receptorNaloxonePrecipitated withdrawalCeiling effectCYP3A4Clinical Opiate Withdrawal Scale (COWS)Bridge programPolysubstance useXylazineMotivational Interviewing (MI)Acceptance and Commitment Therapy (ACT)
Test your understanding
- How does buprenorphine's mechanism of action as a partial agonist contribute to its safety profile compared to full opioid agonists?
- What are the primary risks associated with initiating buprenorphine too soon after using other opioids, and how can this be prevented?
- Explain the role of naloxone in buprenorphine formulations and why it is included.
- What are the key implications of the removal of the X waiver for healthcare providers and patients seeking treatment for opioid use disorder?
- How do adulterants like xylazine in the illicit drug supply complicate the treatment of opioid use disorder with buprenorphine, and why is naloxone ineffective against them?
- Why is a slow, gradual taper recommended when discontinuing buprenorphine, and what are the potential consequences of stopping too quickly?